S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
NASDAQ:ARLZ

Aralez Pharmaceuticals (ARLZ) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.03
$0.03
50-Day Range
N/A
52-Week Range
$0.02
$2.98
Volume
N/A
Average Volume
5.13 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ARLZ stock logo

About Aralez Pharmaceuticals Stock (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.


ARLZ Stock News Headlines

Amneal Pharmaceuticals, Inc. (AMRX)
Aveo Pharmaceuticals
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
MGC Pharmaceuticals Ltd (MXCM)
See More Headlines
Receive ARLZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aralez Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2017
Today
3/01/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ARLZ
CUSIP
73941U10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Adrian Adams (Age 67)
    CEO & Director
  • Mr. Andrew I. Koven (Age 60)
    Pres & Chief Bus. Officer
  • Mr. Michael Kaseta (Age 42)
    Chief Financial Officer
  • Dr. James Patrick Tursi (Age 53)
    Chief Medical Officer
  • Mr. John E. Barnhardt CPA (Age 68)
    Principal Accounting Officer and VP of Fin. & Admin.














ARLZ Stock Analysis - Frequently Asked Questions

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) released its quarterly earnings results on Thursday, November, 9th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.02. The company had revenue of $24.30 million for the quarter, compared to analysts' expectations of $22.87 million. The business's quarterly revenue was up 78.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.32) EPS.

What other stocks do shareholders of Aralez Pharmaceuticals own?
This page (NASDAQ:ARLZ) was last updated on 3/1/2024 by MarketBeat.com Staff